Fig. 5: Protein modulation of combined treatment between FLT3 inhibitors and autophagy inhibitors. | Cell Death Discovery

Fig. 5: Protein modulation of combined treatment between FLT3 inhibitors and autophagy inhibitors.

From: Autophagy inhibition potentiates the antileukemic effect of FLT3 inhibitors and overcomes resistance in FLT3-ITD acute myeloid leukemia

Fig. 5: Protein modulation of combined treatment between FLT3 inhibitors and autophagy inhibitors.The alternative text for this image may have been generated using AI.

A Analysis of the effect of midostaurin and quizartinib combined or not with chloroquine, bafilomycin A1 or ROC-325 in the MOLM13 cell line. Western blotting analysis was performed on total cell extracts from cells treated with vehicle, midostaurin (12 nM) or quizartinib (1.2 nM) alone or combined with chloroquine (5 μM), bafilomycin A1 (2.5 nM) or ROC-325 (1 μM) for 48 h. B Heatmap for the protein expression analysis in MOLM13 cells treated with vehicle, midostaurin (12.5 nM), chloroquine (10 µM) and combination for 48 h. The data represent the fold change of the vehicle-treated cells, and the downregulated and upregulated proteins are shown in blue and red, respectively. C Venn diagram analysis of downregulated proteins expressed in midostaurin monotherapy, chloroquine monotherapy and combination. D Volcano plot demonstrates the differentially expressed proteins comparing vehicle vs. combination and monotherapy with midostaurin vs. combination. E GSEA of the MOLM13 proteome comparing vehicle vs. combination and combination vs. monotherapy with chloroquine.

Back to article page